TET2 mutation

We leveraged the Phase III Fondazione Italiana Linfomi FOLL12 trial, which treated patients with advanced-stage FL with R-CHOP or R-Bendamustine, to evaluate the role of myeloid CH at baseline and after chemoimmunotherapy (CIT). Patients acquiring fit DDR clones (N = 37) had inferior long-term outcomes, including independent increased risk of second malignancies (hazard ratio [HR] 2.63, P = 0.035) that developed in 28 patients, and shorter OS (HR 3.28, P = 0.008). CH emerges as a novel and potentially valuable biomarker in FL, capable of predicting long-term toxicities that are key endpoints in indolent lymphoid malignancies characterized by long-lasting survival.

Despite standard induction and intrathecal chemotherapy, bone marrow assessment demonstrated primary refractory disease. This case highlights aggressive secondary AML with adverse biology, CNS involvement, and induction failure.

Categorizing patients on the basis of MR gene mutations revealed that the inferior survival of sole +8 patients may be attributed to the high frequency of MR gene mutations in these patients. These findings indicate the importance of genetic mutations, specifically MR genes, in sole +8 AML.

P2, N=25, Suspended, Abhay Singh, MD MPH | Recruiting --> Suspended

This case establishes the shared clonal origin between AITL and BL arising in the setting of CH and provides additional biological insight into the development of B-cell lymphoma associated with AITL.

In this real-world cohort, CHIP, particularly TET2 mutations, was associated with prolonged ICI treatment duration. These findings suggest that CHIP may serve as a potential biomarker for predicting the clinical benefit of ICIs in advanced solid tumors.

Core-binding factor (CBF) acute myeloid leukemia (AML) with t(8;21)(q22;q22)/RUNX1::RUNX1T1 is typically considered as a favorable-risk AML in the context of cytarabine-based intensive chemotherapy...Here, we report the case of a young patient diagnosed with CBF-AML and RUNX1::RUNX1T1 fusion gene, carrying a rare and complex three-way t(8;11;21)(q22;q13;q22) translocation, with mutated KIT, ASXL1 and TET2 genes, transforming into an aggressive and multi-refractory mediastinal myeloid sarcoma. This case illustrates that this scarcely reported variant might negatively impact the favorable prognosis of CBF-AML.

Emerging studies also suggest potential therapeutic strategies for TET2-CHIP-associated cardiovascular disease. This review summarizes current understanding of TET2 biology, mechanisms of TET2-CHIP development, and its cardiovascular implications.

No significant differences in genetic profiles, treatment response, or outcomes were observed between patients with and without CML-like features. This study provides a comprehensive genomic and clinical characterization of BCR::ABL1-positive MPAL, supporting improved risk stratification and future therapeutic strategies.

Multivariate analysis showed that the Charlson comorbidity index (CCI) (OR=10.540, P=0.003), platelet count (OR=10.980, P=0.001), coagulopathy (OR=7.126, P=0.005), CD34(-)/HLA-DR(-) immunophenotype (OR=6.416, P=0.002), and infection (OR=59.080, P<0.001) were independent risk factors for ED in NPM1(mut) AML patients. Severe infection and bleeding were the main risk factors for ED in NPM1(mut) AML patients, and the CD34(-)/HLA-DR(-) immunophenotype should be considered in risk stratification and clinical management of patients with NPM1(mut) AML to guide early intervention.